Fig. 3From: Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective studySubgroup analyses of disease-free survival. HR hazard ratio, CI confidence interval, ECOG eastern cooperative oncology group, EGFR epidermal growth factor receptor, TKIs tyrosine kinase inhibitors, SBRT stereotactic body radiation therapyBack to article page